Stereotaxis Submits EMAGIN Catheter for Regulatory Clearance as it Pioneers Robotics for Endovascular Surgery

Core Insights - Stereotaxis has announced the FDA regulatory submission for the EMAGIN™ 5F, the first robotically navigated catheter aimed at expanding Robotic Magnetic Navigation into the endovascular field [1][2] - The EMAGIN brand will include a range of robotic catheters and wires, with the 5F catheter designed for navigating complex vascular structures [2] - The company anticipates launching the EMAGIN 5F in the second half of 2025, following expected regulatory approvals [3][4] Company Overview - Stereotaxis is a leader in surgical robotics for minimally invasive endovascular interventions, with a mission to develop robotic systems that enhance patient care and operational efficiency [5] - The technology has been utilized in over 150,000 procedures globally, indicating a strong market presence and acceptance [5] Industry Impact - Robotic Magnetic Navigation is positioned to address significant clinical challenges in neurointerventional and interventional cardiology, enhancing safety and precision in complex procedures [3][4] - Experts in the field express optimism about the potential of the EMAGIN catheter to improve outcomes in various challenging medical procedures [3]